Dronedarone in High-Risk Permanent Atrial Fibrillation

  • Connolly S
  • Camm A
  • Halperin J
 et al. 
  • 161

    Readers

    Mendeley users who have this article in their library.
  • 392

    Citations

    Citations of this article.

Abstract

Background Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. Methods We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. Results After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.9...

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Stuart J. Connolly

  • A. John Camm

  • Jonathan L. Halperin

  • Campbell Joyner

  • Marco Alings

  • John Amerena

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free